Researchers from Aarhus University in Denmark published research indicating that Parkinson’s disease is actually two types of the disease.
Europe’s healthcare regulator endorsed using dexamethasone to treat Covid-19 patients with breathing difficulties, paving the way for the steroid to become the region’s second approved treatment for the respiratory illness.
CHMP Recommends Approval of Lilly’s Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis — Positive Opinion is the First Regulatory Action for Baricitinib as an Atopic Dermatitis Medicine INDIANAPOLIS, Sept. 18, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency’s (EMA) Committee for […]
Adult obesity is rising in the United States – with a greater impact on racial and ethnic minorities – a U.S. Centers for Disease Control (CDC) report showed, at a time when the health condition is seen causing heightened risk for severe Covid-19.
Sinovac Biotech plans to start a clinical trial of the Chinese vaccine maker’s experimental coronavirus vaccine with children and adolescents in September, widening the company’s test on a shot that is already in the final stage of study with adults.
The National Institutes of Health launched two of the three late-stage clinical trials to test the effectiveness and safety of different types of blood thinners in treating Covid-19 among adults.
Merck reported positive results regarding the safety, tolerability and immunogenicity in two Phase III studies for V114, the company’s investigational 15-valent pneumococcal conjugate vaccine.
A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.
The U.S. Food and Drug Administration approved Athena Bioscience LLC’s Qdolo (tramadol hydrochloride) Oral Solution 5mg/1mL C-IV, an opioid agonist indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
The U.S. Food and Drug Administration approved Bristol Myers Squibb’s Onureg (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission or CR with incomplete blood count recovery following intensive induction chemotherapy and who are not able to complete intensive curative therapy.